Concept Architecture
Concept
Theoretically, Half-Life is the time required for the quantity of a substance undergoing first-order exponential decay to decrease to one-half of its initial value. The concept originates from radioactive decay theory but is equally fundamental in pharmacokinetics, where it describes the elimination of drugs from the body. In health economics, half-life is incorporated into pharmacokinetic and pharmacodynamic models, influencing dosing schedules, treatment effectiveness, adherence assumptions and economic evaluations of pharmaceuticals.
Mathematically, half-life is derived from the exponential decay equation describing first-order elimination. It is inversely proportional to the elimination rate constant and, in pharmacokinetics, is directly related to drug clearance and volume of distribution. The mathematical framework enables prediction of drug concentrations over time and estimation of dosing intervals required to maintain therapeutic concentrations.
In practice, half-life is estimated from plasma concentration-time data using pharmacokinetic studies and nonlinear regression techniques. It is routinely reported during drug development and regulatory evaluation. Within health economics, half-life informs model assumptions regarding treatment duration, adherence, persistence, adverse events, therapeutic effectiveness and resource utilisation, particularly in decision-analytic and pharmacoeconomic models.
Purpose
Used to quantify the rate of exponential drug elimination or decay, supporting pharmacokinetic analysis, dosing optimisation and health economic evaluation of pharmaceutical interventions.
Mathematical Formulae
Primary Formula
t� = ln(2) / k
Supporting Formulae
Exponential decay:
C(t) = C?e???
Relationship to clearance and volume of distribution:
t� = (ln(2) ? Vd) / CL
Remaining concentration after time t:
C(t) = C? ? (1/2)^(t/t�)
Related Mathematical Methods
- First-Order Kinetics
- Exponential Decay
- Nonlinear Regression
- Pharmacokinetic Modelling
- Compartmental Analysis
- Population Pharmacokinetic Modelling
Example
A medicine has an elimination rate constant of 0.1155 per hour.
Half-life:
t� = 0.693 � 0.1155
t� = 6.0 hours
If the initial plasma concentration is 80 mg/L, the expected concentration after 12 hours (two half-lives) is:
C(12) = 80 ? (1/2)�
C(12) = 20 mg/L
Excel Implementation
| Function | Example Formula | Health Economics Application |
|---|---|---|
| LN | =LN(2)/B2 | Calculates half-life from the elimination rate constant. |
| EXP | =B2*EXP(-C2*D2) | Calculates drug concentration over time using exponential decay. |
| POWER | =InitialConc*(1/2)^(Time/HalfLife) | Estimates remaining drug concentration after a specified time. |
| LOGEST | =LOGEST(ConcentrationRange,TimeRange) | Estimates exponential decay parameters from pharmacokinetic data. |
| LINEST | =LINEST(LN(ConcentrationRange),TimeRange) | Estimates the elimination rate constant following logarithmic transformation. |
VBA (Optional)
VBA can automate estimation of elimination rate constants, half-lives and concentration-time profiles from pharmacokinetic datasets.
Sources
- Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications.
- Gibaldi M, Perrier D. Pharmacokinetics.
- Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications.
- Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation.
- Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes.
- ISPOR Good Practice Reports.
Related Concepts (2)
Library
Publications
1
Pharmacoeconomics: From Theory to Practice — Renee J. G. Arnold (ed.), 2nd Edition ed., 2021 (CRC Press (Routledge))
An applied, practitioner-oriented pharmacoeconomics reference covering decision modelling, cost of illness, Markov modelling, retrospective database analysis, budget impact, multi-criteria decision analysis, value-based pricing of pharmaceuticals, and reimbursement, with real-world examples.
BookView source →
Frequently Asked Questions (6)
What is a drug's half-life?
The time required for a drug's concentration in the body to fall by half, a key parameter determining dosing frequency.
Source: Rowland & Tozer 2010
What does a drug's half-life tell us about how it leaves the body?
A drug's half-life is the time it takes for the amount of the drug in the body to fall by half. It tells us how quickly a drug is cleared: a short half-life means it disappears fast and must be given often, while a long one means it lingers and can be dosed less frequently. It also governs how long a drug takes to build up to a steady level and how long it takes to wash out after stopping. How fast a drug's concentration halves is what it captures. Rowland and Tozer (2010) describe this.
Source: Rowland & Tozer 2010
Why does half-life matter?
Half-life matters because it determines the dosing frequency needed to maintain a therapeutic concentration and how long a drug remains in the body after it is stopped; drugs with short half-lives need frequent dosing, while those with long half-lives can be given less often. So half-life is important for dosing and for the persistence of a drug's effects, which is why it guides how often a drug is taken, since maintaining effective levels requires dosing appropriate to how quickly the drug is eliminated, and the half-life also indicates how long it takes for the drug to be largely cleared after discontinuation.
Source: Rowland & Tozer 2010
How does half-life affect dosing frequency?
Half-life affects dosing frequency because a drug must be dosed often enough to maintain its concentration in the effective range: a short half-life, with rapid elimination, requires frequent dosing to prevent levels falling too low, while a long half-life allows less frequent dosing since the drug persists. So half-life determines how often a drug is given, which is why short-half-life drugs are dosed more frequently and long-half-life drugs less often, since the dosing interval must match the rate of elimination to keep the drug at effective levels, making half-life a key factor in designing dosing regimens.
Source: Rowland & Tozer 2010
How does half-life relate to reaching steady state?
Half-life relates to reaching steady state because, with regular dosing, a drug approaches its steady-state concentration over several half-lives, typically reaching close to steady state after about four to five half-lives. So the half-life determines how long it takes for a drug on regular dosing to reach a stable level, which is why drugs with long half-lives take longer to reach steady state, since the accumulation to a stable concentration occurs over multiples of the half-life, and this is relevant for knowing when a drug's full effect will be reached and whether a loading dose is needed to reach it faster.
Source: Rowland & Tozer 2010
What determines a drug's half-life?
A drug's half-life is determined by its clearance, the rate of elimination, and its volume of distribution, how widely it spreads in the body; a lower clearance or a larger volume of distribution lengthens the half-life. So half-life depends on both how quickly the drug is eliminated and how it distributes, which is why it can vary with factors affecting these, such as organ function, since reduced clearance from impaired liver or kidney function prolongs the half-life, and understanding what determines half-life helps in adjusting dosing for individual patients and conditions.
Source: Rowland & Tozer 2010
Trust Record
Verified by Dr Darrin Baines
British health economist
Professional identity: darrinbaines.org
Verification date: 17 Apr 2026
Content version: 1.0.0
Canonical Identity
- Persistent URI
- https://healtheconomics.wiki/concept/half-life
- Term code
- HE-PE-CP-005
Stable URI · Machine-readable · Resolvable · CC BY 4.0